CDK2 and familial pancreatic carcinoma: In both in vitro and in vivo models of pancreatic cancer, mogroside V (16) has tumor growth inhibitory activity by promoting apoptosis and cell cycle arrest in pancreatic cancer cells (PANC-1 cells), possibly through modulation of the STAT3 signalling pathway, promoting cell proliferation (CCND1, CCNE1 and CDK2), while also upregulating cell cycle inhibitors (CDKN1A and CDKN1B) [109].